NDC11 72266014201
This exact 11-digit normalized identifier can correspond to more than one FDA hyphenation. FDA.report preserves the exact identifier and exposes every structurally valid candidate without guessing.
Possible FDA NDC forms#
| Package NDC | Product root |
|---|---|
| 72266-0142-01 | 72266-0142 |
| 72266-0142-1 | 72266-0142 |
| 72266-142-01 | 72266-142 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| STRENZA PLUS | MOXIFLOXACIN 0.5%, BROMFENAC 0.09%, PREDNISOLONE ACETATE 1% | Brisk Pharmaceuticals | 2df9064c-0527-4c21-e063-6294a90a56d8 | 2025-02-12 | 72266-142-01 72266014201 | |
| BROMFENAC | BROMFENAC | Fosun Pharma USA Inc. | a8f1d85a-5585-4632-bdfa-a54a535b5c17 | 2025-01-22 | Warnings, Adverse reactions | 72266-142-01 72266-142 72266014201 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.